BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Seismic Pharma readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Seismic Pharma's drugs run\, from
  ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07583446-603@assetmemo.bio
DTSTAMP:20261121T005601Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Istaroxime: Phase 2/3 readout est. (NCT07583446)
DESCRIPTION:Istaroxime\, phase 2/3\, Heart Failure.\nStudy: Randomized Eval
 uation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic 
 Shock\nEstimated primary completion: December 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/istaroxime#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07583446
URL:https://assetmemo.bio/drug/istaroxime#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
